Prognostic and predictive factors in breast cancer by immunohistochemical analysis

Modern Pathology

Volumn 11, Issue 2, 1998, Pages 155-168

  Allred, D Craig ^a   Harvey, Jennet M ^c   Berardo, Melora ^d   Clark, Gary M ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Outpatient Cytopathology Center   (United States)

Author keywords

Breast cancer; Immunohistochemistry; Prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; ONCOGENE C ERB; OUTCOMES RESEARCH; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK FACTOR;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031915998     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (186)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15, 71-85.
2. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippincott-Raven; 1996. p. 461-85.
3. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-19.
4. Klijn JG, Berns EM, Foekens JA. Prognostic factors and response to therapy in breast cancer. Cancer Surv 1993;18: 165-98.
5. Foekens JA. Cell biological prognostic factors in breast cancer: a review. J Clin Immunoassay 1991;14:1684-95.
6. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:1-9.
7. Henson DE, Fielding P, Grignon DJ, Page DL, Hammond ME, Nash G, et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Arch Pathol Lab Med 1994;119:1109-12.
8. Goldhirsch A, Wood WC, Senn H-J, Click JH, Gelber RD. International consensus panel on the treatment of primary breast cancer. Eur J Cancer 1995;31A:1754-9.
9. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
10. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
11. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB Jr. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990;125: 107-13.
12. DeSombre ER, Thorpe SM, Rose C, Blough RR, Andersen KW, Rasmussen BB, et al. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res 1986;46 (8 Suppl):S4256-S4264.
13. Walker KJ, Bouzubar N, Robertson J, Ellis IO, Elston CW, Blarney RW, et al. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res 1988; 48:6517-22.
14. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989;49:1052-6.
15. Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990;66:1663-70.
16. Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 1990;50:7057-61.
17. Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen B, et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 1990;26:442-9.
18. Cowen PN, Teasdale J, Jackson P, Reid BJ. Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay. Histopathology 1990;17:319-25.
19. Seymour L, Meyer K, Esser J, MacPhail P, Behr A, Bezwoda WR. Estimation of PR and ER by immunocytochemistry in breast cancer. Comparison with radioligand binding methods. Am J Clin Pathol 1990;94 (4 Suppl 1):S35-S40.
20. Andersen J, Thorpe SM, Rose C, Christensen I, Rasmussen BB, Poulsen HS. Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. Acta Oncol 1991;30:685-90.
21. Querzoli P, Ferretti S, Marzola A, Tassinari D, Indelli M, Marchetti E, et al. Clinical usefulness of estrogen receptor immunocytochemistry in human breast cancer. Tumori 1992;78:287-90.
22. Robertson JFR, Bates K, Pearson D, Blarney RW, Nicholson RI. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 1992;65:727-30.
23. Hurlimann J, Gebhard S, Gomez F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27, and cathepsin D in invasive ductal breast carcinomas. Histopathology 1993; 23:239-48.
24. Hanna W, McReady DR, Chapman JW, Mobbs BG, Trudeau ME. The predictive value of ERICA in breast cancer recurrence. A univariate and multivariate analysis. Mod Pathol 1993;6:748-54.
25. Battifora H, Mehta P, Ahn C, Esteban JM. Estrogen receptor immunohistochemical assay in paraffin-embedded tissue. A better gold standard? Appl Immunohistochem 1993;1:39-45.
26. Esteban JM, Ahn C, Mehta P, Battifora H. Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 1994;102:158-62.
27. Kommoss F, Pfisterer J, Idris T, Giese E, Sauerbrie W, Schafer W, et al. Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Anal Quant Cytol Histol 1994;16:203-210.
28. Beck T, Weikel W, Brumm C, Wilkens C, Poloow K, Knapstein P-G. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol 1994;53: 220-7.
29. Stierer M, Rosen H, Weber R, Hanak H, Auerbach L, Spona J, et al. A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Breast Cancer Res Treat 1995;36:11-21.
30. Ferno M, Andersson C, Fallenius G, Idvall I, Souther Swedish Breast Cancer Group. Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. Acta Oncol 1996;35:17-22.
31. Layfield LJ, Saria EA, Conlon DH, Kerns B-JM. Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance. J Surg Oncol 1996;61:177-84.
32. Ferrer Roca O, Ramos A, Diaz Cardama A. Immunohistochemical correlation of steroid receptors and disease-free interval in 206 consecutive cases of breast cancer: validation of telequantification based on global scene segmentation. Anal Cell Pathol 1995;9:151-63.
33. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 1997;43:221-8.
34. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Jr. Estrogen receptor analysis. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-21.
35. Pertschuk LP, Eisenberg KB, Carter AC, Feldman JG. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer 1985;55: 1513-8.
36. Ozzello L, De Rose C, Habif DV, Lipton R. Immunostaining of estrogen receptors in paraffin sections of breast cancers using anti-estrophilin monoclonal antibodies. In: Ceriani R, editor. Monoclonal antibodies in breast cancer. Boston: Martinus Hijhoff; 1985. p. 3-12.
37. Jonat W, Maass H, Stegner HE. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res 1986;46(Suppl 8):S4296-S4298.
38. McClelland RA, Berger U, Miller LS, Powles TJ, Jensen EV, Coombes RC. Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res 1986;46(Suppl 8): S4241-S4243.
39. Berger U, Mansi JL, Wilson P, Coombes RC. Detection of estrogen receptor in bone marrow from patients with metastatic breast cancer. J Clin Oncol 1987;5:1779-82.
40. Burton GV, Flowers JL, Cox EB, Leight GS, Dent BA, Geisinger JR, et al. Estrogen receptor determination by monoclonal antibody in fine-needle aspiration breast cancer cytologies: a marker of hormone response. Breast Cancer Res Treat 1987;10:287-91.
41. Coombes RC, Berger U, McClelland R, Trott PA, Powles TJ, Wilson P, et al. Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet 1987;ii:701-3.
42. De Lena M, Marzullo F, Simone G, Labriola A, Tommasi S, Petroni S, et al. Correlation between ERICA and DCC assay in hormone receptor assessment of human breast cancer. Oncology 1988;45:308-12.
43. Andersen J, Poulsen HS. Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: correlation with clinical endocrine response. J Steroid Biochem 1988;30:337-9.
44. Hawkins RA, Sangster K, Tesdale A, Levack PA, Anderson EDC, Chetty U, et al. The cytochemical detection of oestrogen receptors in fine-needle aspirates of breast cancer: correlation with biochemical assay and prediction of response to endocrine therapy. Br J Cancer 1988;58:77-80.
45. Gaskell DJ, Hawkins RA, Sangsteri K, Chetty U, Forrest APM, et al. Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet 1989;i: 1044-6.
46. Andersen J, Poulsen HS. Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 1989;64:1901-8.
47. Sklarew RJ, Bodmer SC, Pertschuk LP. Quantitative imaging of immunocytochemical (PAP) estrogen receptor staining patterns in breast cancer sections. Cytometry 1990;11:359-78.
48. McClelland RA, Finlay P, Walker KJ, Nicholson D, Robertson JFR, Blamey RW, et al. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 1990;50:3545-50.
49. Goulding H, Pinder S, Cannon R, Pearson D, Nicholson R, Snead D, et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 1995;26:291-4.
50. Pertschuk LP, Feldman JG, Kim Y-D, Braithwaite L, Scneider F, Braverman AS, et al. Estrogen receptor immunocytochemistry in paraffin-embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol-based ligand-binding assays. Cancer 1996;77:2514-9.
51. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-51.
52. Clark GM, Harvey JM, Osborne CK, Allred DC. Estrogen receptor status (ER) determined by immunohistochemistry (IHC) is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients [abstract]. Proc Am Soc Clin Oncol 1997;16:129A.
53. McGuire WL, Chamness GC, Fuqua SA. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991;5: 1571-7.
54. Fuqua SA, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995;35: 233-41.
55. Pertschuk LP, Feldman JG, Eisenberg KB, Carter AC, Thelmo WL, Cruz WP, et al. Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease-free survival, and clinical endocrine response. Cancer 1988;62: 342-9.
56. Gasparini G, Pozza F, Dittadi R, Melis S, Cazzavillan S, Bevilacqua P. Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer. J Cancer Res Clin Oncol 1992;118:557-63.
57. Muller-Holzner E, Zeimet AG, Daxenbichler G, Marth C, Muller LC, Dapunt O. Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases. Breast Cancer Res Treat 1993;25:47-55.
58. Berardo M, Clark GM, de Moor C, Osborne CK, Weigand RA, Allred DC. Prognostic and predictive properties of immunohistochemical progesterone receptors in breast cancer [abstract]. Proc Am Soc Clin Oncol 1995;14:110A.
59. Rajkumar T, Gullick WJ. The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 1994;29: 3-9.
60. De Potter CR, Schelfhout A-M. The neu-protein and breast cancer. Virchows Archiv 1995;426:107-15.
61. Tommasi S, Paradiso A, Mangia A, Barletta A, Simone G, Slamon DJ, et al. Biological correlation between HER-2/neu and proliferative activity in human breast cancer. Anti Cancer Res 1991;11:1395-400.
62. Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis, and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-5.
63. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. erbB-2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991;6:137-43.
64. De Potter CR, Quatacker J. The p185/erbB-2 protein is localized on cell organelles involved in cell motility. Clin Exp Metastasis 1993;11:453-61.
65. De Potter CR. The neu oncogene: more than a prognostic indicator? Hum Pathol 1994;25:1264-8.
66. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
67. Nagai MA, Marques LA, Torloni H, Brentani MM. Genetic alterations in c-erbB-2 proto-oncogene as prognostic markers in human primary breast tumors. Oncology 1993; 50:412-7.
68. Tsuda H, Hirohashi S, Shimosato Y, Tanaka Y, Hirota T, Tsugane S, et al. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 1990;81:327-32.
69. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10: 599-605.
70. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, et al. Prognostic significance of c-erbB-2 expression in node-negative breast cancer. Br J Cancer 1993;67: 625-9.
71. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SAW, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50:4332-7.
72. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51:944-8.
73. Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-43.
74. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991;51:3296-303.
75. Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Erashi M, Thomas M, et al. c-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 1992;69:2953-60.
76. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA. The relationship between c-erbB-2 expression, S-phase fraction, and prognosis in breast cancer. Br J Cancer 1991;63:444-6.
77. Paterson MC, Dietrich KD, Kanyluk J, Paterson AHG, Lees AW, Jamil N, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991;54:556-67.
78. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Immunohistochemical detection of HER2/neu in patients with axillary lymph node-negative breast carcinoma. Cancer 1995;75:1320-6.
79. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992;10:1044-8.
80. Albanell J, Bellmunt J, Molina R, Garcia M, Caragol I, Bermejo B, et al. Node-negative breast cancers with p53(-)l HER2-neu(-) status may identify women with very good prognosis. Anticancer Res 1996;16:1027-32.
81. Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, et al. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 1991;163:105-10.
82. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismonidi P. Prognostic and predictive relevance of c-erbB-2 and ras expression in node-positive and negative-breast cancer. Anticancer Res 1994;14:1441-50.
83. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Seve-Soderborgh J, Anbazhagan, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10: 1049-56.
84. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns B-JM, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early-stage breast cancer. Annu Surg 1994;219:332-41.
85. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
86. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;35:283-91.
87. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991;49:44-9.
88. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlar V, Kitchen P, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-42.
89. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, et al. The long-term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991;63:447-50.
90. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-12.
91. Anbazhagan R, Gelber RD, Bettelheim R, Goldhirsch A, Gusterson BA. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Annu Oncol 1991;2:47-53.
92. Borresen A-L, Ottestad L, Gaustad A, Andersen TI, Heikkila R, Jahnsen T, et al. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 proto-oncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 1990;62:585-90.
93. Hartmann LC, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956-63.
94. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
95. Schonborn I, Zschiesche W, Spitzer E, Minguillon C, Mohner M, Ebeling K, et al. c-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res Treat 1994;29:287-95.
96. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. Cancer 1994;73:2359-65.
97. Battifora H, Gaffey M, Esteban J, Mehta P, Bailey A, Fancett C, et al. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod Pathol 1991;4:466-74.
98. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, et al. c-erbB-2 and ras expression levels in breast cancer are correlated and show a cooperative association with unfavorable clinical outcome. Int J Cancer 1991;47:833-8.
99. Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, Meli S, Boracchi P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992;10:686-95.
100. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-438.
101. Heintz NH, Leslie KO, Rogers LA, Howard PL. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1990;114:160-3.
102. Horiguchi J, Iino Y, Takei H, Yokoe T, Ishida T, Morishita Y. Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. Oncology 1994;51:47-51.
103. Ji H, Lipponen P, Aaltomaa S, Syrjanen S, Syrjanen K. c-erbB-2 oncogene related to p53 expression, cell proliferation, and prognosis in breast cancer. Anticancer Res 1993; 13:1147-52.
104. Kury R, Sliutz G, Schemper M, Reiner G, Reiner A, Jakesz R, et al. HER-2 oncogene amplification and overall survival of breast carcinoma patients. Eur J Cancer 1990;26:946-9.
105. Lonn U, Lonn S, Nilsson B, Stenkvist B, et al. Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features. Breast Cancer Res Treat 1994;29:237-45.
106. May E, Mouriesse H, May-Levin F, Qian JF, May P, Delarne J-C. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 1990;62:430-5.
107. Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A. Prognostic significance of the coexpression of p53 and c-erbB-2 proteins in breast cancer. J Pathol 1996;179:31-8.
108. Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Prognostic significance of coexpression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 1992;164:323-6.
109. Pierce LJ, Merino MJ, D'Angelo T, Barker EA, Gilbert L, Cowan KH, et al. Is c-erbB2 a predictor for recurrent disease in early stage breast cancer? Int J Rad Oncol Biol Phys 1994;28:395-403.
110. Schroeter CA, De Potter CR, Rathsmann K, Willighagen RGJ, Greep JC. c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. Br J Cancer 1992;66:728-34.
111. Takikawa Y, Noguchi M, Kitagawa H, Thomas M. Immunohistochemical detection of p53 and c-erbB-2 proteins: prognostic significance in operable breast cancer. Breast Cancer 1994;1:17-23.
112. Tanner B, Friedberg T, Mitze M, Beck T, Oesch F, Knapstein PG. c-erbB-2 oncogene expression in breast carcinoma analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters. Gynecol Oncol 1992;47:228-33.
113. Terrier P, Mouriesse H, Loridon B, Gotteland M, May-Levin F, Delarue JC. Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein overexpression in human breast cancer. Acta Oncol 1996;35:23-30.
114. Stal O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstesen JM, et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31:2185-90.
115. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, et al. c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14:2702-8.
116. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, et al. erbB-2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137-44.
117. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118-21.
118. Thor AD, Budman DR, Berry DA, Muss HB, Kute T, Barcos M, et al. Selecting patients for higher dose adjuvant CAF: c-erbB-2, p53, dose, and dose intensity in stage II, node+ breast cancer [abstract]. Proc Am Soc Clin Oncol 1997;16: 128A.
119. Shimamura A, Fisher DE. p53 in life and death. Clin Cancer Res 1996;2:435-40.
120. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-9.
121. Thor AD, Moore II DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
122. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14.
123. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85: 200-6.
124. Noguchi M, Kitagawa H, Kinoshita K, Miyazaki I, Saito Y, Mizukami Y. Prognostic significance of p53 and c-erbB-2 expression in operable breast cancer. Int J Clin Oncol 1993; 2:587-91.
125. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis. Hum Pathol 1993;24:469-76.
126. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993;85:965-70.
127. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993; 72:3641-7.
128. Gasparini G, Bevilacqua P, Boracchi P, Maluta S, Pozza F, Barbareschi M, et al. Prognostic value of p53 expression in early stage breast carcinoma compared with tumour angiogenesis, epidermal growth factor receptor, c-erbB-2, cathepsin D, DNA ploidy, parameters of cell kinetics, and conventional features. Int J Oncol 1994;4:155-62.
129. Elledge RM, Clark GM, Fuqua SAW, Yu YY, Allred DC. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 1994;54:3752-7.
130. Domagala W, Striker G, Szadowska A, Dukowicz A, Harezga B, Osborn M. p53 protein and vimentin in invasive ductal NOS breast carcinoma: relationship with survival and sites of metastases. Eur J Cancer 1994;30A:1527-34.
131. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, et al. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 1995;36:71-81.
132. Stenmark-Askmalm M, Stal O, Olsen K, Nordenskjold B, Arnesson LG, Hatschek T, et al. p53 as a prognostic factor in stage I breast cancer. Br J Cancer 1995;72:715-9.
133. Patel DD, Bhatavdekar JM, Chikhlikar PR, Ghosh N, Suthar TP, Shah NG, et al. Node-negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 1996;62:86-92.
134. Seshadri R, Leong ASY, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis. Int J Cancer 1996;69:135-41.
135. Visscher DW, Sarkar FH, Wykes S, Kothari K, Mocaska J, Crissman J. Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. Arch Pathol Lab Med 1993;117:973-6.
136. Gohring UJ, Scharl A, Heckel C, Ahr A, Crombach G. p53 protein in 204 patients with primary breast carcinoma: immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet 1995;256:139-46.
137. Borg A, Lennerstrand J, Stenmark-Askmalm M, Ferno M, Brisfors A, Ohrvik A, et al. Prognostic significance of p53 overexpression in primary breast cancer: a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 1995;71:1013-7.
138. Sawan A, Randall B, Angus B, Wright C, Henry JA, Ostrowski J, et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 1992;168:23-8.
139. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borreses A-L. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993;68:540-8.
140. Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993;55:51-6.
141. Thorlacius S, Borresen AL, Eyfjord JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 1993;53:1637-41.
142. Jacquemier J, Moles JP, Penault-Llorca F, Adelaide J, Torrente M, Viens P, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994;69: 846-52.
143. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Palma PD, Caffo O, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
144. Cunningham JM, Ingle JN, Jung SH, Cha SS, Wold LE, Farr G, et al. p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. J Natl Cancer Inst 1994;86:1871-3.
145. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995;1:1029-34.
146. Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, et al. p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 1996;73:29-35.
147. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173-82.
148. Pietilainen T, Lipponen P, Aaltomaa S, Eskilinen M, Kosma V-M, Syrjanen K. Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 1995; 177:225-32.
149. DeWitte HH, Foekens JA, Lennerstrand J, Smid M, Look MP, Klijn JGM, et al. Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 1996;69:125-30.
150. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991;164:75-81.
151. Hanzal E, Gitsch G, Kohlberger P, Dadak CH, Miechowiecka N, Brietenecker G. Immunohistochemical detection of mutant p53 suppressor gene product in patients with breast cancer: influence on metastasis free survival. Anticancer Res 1992;12:2325-30.
152. Bosari S, Lee AK, Viale G, Heatley GJ, Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Archiv 1992;421:291-5.
153. Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, et al. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 1992;66:583-8.
154. Wiltschke C, Kindas-Muegge I, Steininger A, Reiner A, Reiner G, Preis PN, et al. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol 1994;120:737-42.
155. Hurlimann J. Prognostic value of p53 protein expression in breast carcinomas. Pathol Res Pract 1993;189:996-1003.
156. Caleffi M, Teague MW, Jensen RA, Vnencak-JOnes CL, Dupont WD, Parl FF. p53 gene mutations and steroid receptor status in breast cancer. Cancer 1993;73:2147-56.
157. Haerslev T, Jacobsen GK. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hum Pathol 1995;26:295-301.
158. Schonborn I, Minguillon C, Lichtenegger W, Zschiesche W, Spitzer E. c-erbB-2, EGF receptor, p53, and PCNA: the prognostic significance of recent tumor markers for lymph node negative breast cancer. Geburtshilfe Frauenheilkd 1995;55: 566-71.
159. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, et al. Expression of ras, p21, p53, and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995;72:1259-66.
160. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995;13: 821-30.
161. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, et al. bcl-2, p53, and response to tamoxifen in ER-positive metastatic breast cancer. J Clin Oncol 1997;15: 1916-22.
162. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991;82:835-40.
163. Berns EMJJ, Klijn JGM, Smid M, Van Staveren IL, Look MP, Van Putten WLJ, et al. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosom Cancer 1996;16:170-9.
164. Jansson T, Inganas M, Sjogren S, Norberg T, Lindgren A, Holmberg L, et al. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995;13:2745-51.
165. Silvestrini R, Benini E, Veneroni S, Daidone MG, Pomasic G, Squicciarini P, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996;14:1604-10.
166. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature 1993;362: 849-52.
167. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
168. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
169. Fan S, Smith ML, Rivet DJ II, Duba D, Zhan Q, Kohn K, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55: 1649-54.
170. Shao Z-M, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, et al. p53-independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995;11:493-504.
171. Stal O, Skoog L, Rutqvist LE, Cartensen JM, Wingren S, Sullivan S, et al. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 1994;70:1258-62.
172. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995;87:1254-6.
173. Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994;57: 822-9.
174. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, et al. Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989;59:943-7.
175. Weikel W, Beck T, Mitze M, Knapstein PC. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 1991;18:149-54.
176. Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa APM, et al. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer 1993;29A: 1509-13.
177. Railo M, Nordling S, von Boguslawsky K, Lievonen M, Kyllonen L, Von Smitten K. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 1993;68:579-83.
178. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer 1993;71:3926-31.
179. Rudas M, Gnant MFX, Mittlbock M, Neumayer R, Kummer A, Jakesz R, et al. Thymidine-labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 1994;32:165-75.
180. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Am J Clin Pathol 1995;104:42-9.
181. Brown RW, Allred DC, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 1996;2:585-92.
182. Veronese SM, Maisano C, Scibilla J. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res 1996;16:2717-22.
183. Pierga J-Y, Leroyer A, Viehl P, Mosseri V, Chevillard S, Magdelenat H. Long-term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 1996;37: 57-64.
184. Haerslev T, Jacobsen GK, Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 1996;37:101-13.
185. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, Von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991;67:421-8.
186. Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.